Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Logo

The stock of Inovio Pharmaceuticals Inc (NASDAQ:INO) registered a decrease of 14.71% in short interest. INO’s total short interest was 11.74 million shares in December as published by FINRA. Its down 14.71% from 13.76M shares, reported previously. With 1.09 million shares average volume, it will take short sellers 11 days to cover their INO’s short positions. The short interest to Inovio Pharmaceuticals Inc’s float is 13.16%.

The stock increased 0.37% or $0.01 during the last trading session, reaching $2.72. About 512,667 shares traded. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has declined 54.66% since December 15, 2018 and is downtrending. It has underperformed by 54.66% the S&P500.

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The company has market cap of $272.03 million. The Company’s SynCon immunotherapy design has the ability to break the immune systemÂ’s tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It currently has negative earnings. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus.

More notable recent Inovio Pharmaceuticals, Inc. (NASDAQ:INO) news were published by: which released: “Is Inovio Pharmaceuticals a Buy? – Nasdaq” on November 27, 2019, also with their article: “Inovio Pharmaceuticals, Inc. (NASDAQ:INO): Time For A Financial Health Check – Yahoo Finance” published on June 10, 2019, published: “Inovio Pharmaceuticals (INO) Reports Q3 Loss, Misses Revenue Estimates – Nasdaq” on November 12, 2019. More interesting news about Inovio Pharmaceuticals, Inc. (NASDAQ:INO) were released by: and their article: “Inovio Pharmaceuticals Inc (INO) Q3 2019 Earnings Call Transcript – The Motley Fool” published on November 13, 2019 as well as‘s news article titled: “Hedge Funds Cashed Out Of Inovio Pharmaceuticals Inc (INO) Too Early – Yahoo Finance” with publication date: November 29, 2019.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Source link